Play­ing catch-up, Roche out­lines plans for a PhI­II he­mo­phil­ia A pro­gram — next year

For now, the big fo­cus in the he­mo­phil­ia A gene ther­a­py race has been cen­tered on fron­trun­ner Bio­Marin, with an ex­pect­ed OK just weeks away, and the crew from Sang­amo/Pfiz­er, which has been look­ing to play catch-up with a piv­otal study in the works.

But now Roche’s new gene ther­a­py di­vi­sion at Spark has up­dat­ed its own sched­ule, say­ing they’re look­ing at a Phase III start some­time next year as they op­ti­mize the dose and im­munomod­u­la­to­ry reg­i­men in or­der to avoid any fu­ture mishaps that could de­rail the pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.